BioCentury
ARTICLE | Clinical News

Venclexta venetoclax: Phase Ib/II data

May 23, 2016 7:00 AM UTC

Data from 18 evaluable treatment-naive AML patients ages >=65 in the Phase Ib portion of an open-label, dose-escalation, international Phase Ib/II trial showed that once-daily oral Venclexta plus low-...